胰激肽原酶联合递法明治疗糖尿病视网膜病变的疗效观察

Efficacy Observation of Kallidinogenase Combined with Difrarel in the Treatment of Diabetic Retinopathy

目的:观察胰激肽原酶联合递法明治疗糖尿病视网膜病变患者的疗效。方法:选取糖尿病视网膜病变患者120例,按随机数字表法分为对照组A、对照组B和联合组,各40例。对照组A患者给予胰激肽原酶肠溶片240 IU,tid,对照组B患者给予递法明片1.2 g,bid,联合组患者给予同等剂量胰激肽原酶肠溶片和递法明片联合治疗。比较3组患者治疗前后的视力及眼动脉(OA)、视网膜中央动脉(CRA)、睫状后动脉(PCA)的收缩期峰值流速(PSV)、舒张末期流速(EDV)和阻力指数(RI),并评价3组患者的疗效。结果:治疗后,3组患者视力明显上升,OA、CRA、PCA的PSV、EDV水平升高,RI减小,与治疗前比较,差异有统计学意义(P<0.05);联合组患者治疗后的视力及OA、CRA、PCA的PSV、EDV明显高于对照组A、对照组B,RI明显低于对照组A、对照组B,差异有统计学意义(P<0.05);联合组患者总有效率明显高于对照组A和对照组B,差异有统计学意义(P<0.05)。结论:胰激肽原酶联合递法明片能明显改善糖尿病视网膜病变患者视网膜血流动力学指标,提高临床疗效。

OBJECTIVE：To observe therapeutic efficacy of kallidinogenase combined with difrarel in the treatment of diabetic retinopathy.METHODS：120 patients with diabetic retinopathy were randomly divided into control group A,control group B and combination group,with 40 cases in each group.Control group A was given Kallidinogenase enteric-coated tablet 240 IU,tid,control group B was given Difrarel tablet 1.2 g,bid,and combination group equivalent dose of Kallidinogenase enteric-coated tablet combined with Difrarel tablet.The vision,peak systolic velocity（PSV）,end diastolic velocity（EDV）and resistance index（RI）of ophthalmic artery（OA）,central retinal artery（CRA）and posterior ciliary artery（PCA）were compared among 3 groups before and after treatment.Therapeutic efficacy was observed in 3 groups.RESULTS：After treatment,vision of 3 groups significantly improved;PSV and EDV of OA,CRA and PCA increased while RI of OA,CRA and PCR decreased,with statistical significance（P〈0.05）.vision,PSV and EDV of OA,CRA and PCA in combination group were significantly higher than in control group A and control group B after treatment,while RI of OA,CRA and PCA was significantly lower than control group A and control group B,with statistical significance（P〈0.05）;total effective rate of combination group was significantly higher than that of control group A and control group B,with statistical significance（P〈0.05）.CONCLUSIONS：Kallidinogenase combined with difrarel can improve retinal hemodynamics indicator and clinical efficacy of patients with diabetic retinopathy